MED is positioning Trilivy as a complement to GLP-1 medications, combining nutrition and coaching to support sustainable metabolic health and weight management.
Medifast (MED) maintains a strong, cash-heavy balance sheet and trades near liquidation value, but its business model remains uninspiring amid GLP-1 disruption. Q3 2026 revenue declined 19.4% YoY to $72M, with active earning coaches down 47%, though average revenue per coach increased. Management transition and Steamboat Capital's activist involvement signal board-level changes, but the core product and MLM-style distribution remain unchanged.
Medifast NYSE: MED reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management said revenue was within its guidance range and marked a fourth consecutive quarter in which sales stabilized around the mid-$70 million range.
Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.21 per share a year ago.
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for the third quarter ended September 30, 2026. Third Quarter 2026 Revenue: $72.0 million, with revenue per active earning coach of $7,064 Independent active earning coaches of 10,200 Net loss of $17.5 million (non-GAAP adjusted net loss of $2.1 million) Loss per diluted share ("EPS") of $1.57 (non-GAAP a.
MED's Q3 results are likely to face pressure from GLP-1 adoption, shrinking coach numbers and lower sales, while strategic initiatives may offer some support.